FBIO Fortress Biotech, Inc. - Common Stock
NASDAQ · Biotechnology close Oct 2, 2026FBIO Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
FBIO Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
| Ex-date | Split | Type |
|---|---|---|
| Oct. 10, 2023 | 1-for-15 | Reverse |
About Fortress Biotech, Inc. - Common Stock Company overview from Wikipedia
Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.
History
The company was founded in 2006 under the name Coronado Biosciences, initially as an oncology company. In 2011, it was announced that Coronado raised $47.4 million in funding. Shortly thereafter it became a public company by registering all of its private shares as common stock. The company changed its name to Fortress Biotech in April 2015.
In November 2019, Fortress Biotech was ranked number 10 in the 2019 Deloitte Technology Fast 500 annual rankings.
Subsidiaries
Fortress Bio has 10 biopharmaceutical subsidiary companies which cover a range of medical therapy areas, including potential cancer treatments and therapies for rare diseases and conditions. These subsidiaries include Aevitas Therapeutics (formed in 2017), Avenue Therapeutics (formed in 2015), Caelum Biosciences (formed in 2017), Cellvation (formed in 2016), Checkpoint Therapeutics (formed in 2015), Cyprium Therapeutics (formed in 2017), Helocyte (formed in 2015), Journey Medical Corporation (formed in 2014), Mustang Bio (formed in 2015), Tamid Bio (formed in 2017) and Baergic Bio (formed in 2019).
Products
Fortress Bio’s marketed products are developed and commercialized by its subsidiary Journey Medical Corporation. These include Targadox tablets indicated for acne, eczema emollient Ceracade, wound cream Luxamend, topical corticosteroid Triderm, topical broad-spectrum antifungal solution Exelderm, Ala-Quin topical cream for skin conditions, and Ala-Scalp hydrocortisone lotion for skin conditions.
== References ==
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Not enough fundamentals data to compute this ratio group yet.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
Not enough fundamentals data to compute this ratio group yet.
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 13, 2026 | $-0.08 | $-0.20 | 60.8% |
| March 31, 2026 | May 13, 2026 | $-1.13 | $-0.22 | -403.6% |
| Dec. 31, 2025 | $-0.01 | $0.11 | -108.9% | |
| Sept. 30, 2025 | $0.11 | $-0.43 | 125.7% | |
| June 30, 2025 | $-0.50 | $-0.37 | -36.2% | |
| March 31, 2025 | $-0.48 | $-0.50 | 4.9% | |
| Dec. 31, 2024 | $-0.75 | $-0.77 | 2.4% |
Institutional owners (13F) 65 filers · $21.2M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 14 (-2 vs prior Q) | 11 (+2 vs prior Q) | 15 (+3 vs prior Q) | 17 (-1 vs prior Q) | +547K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| VANGUARD GROUP INC | $4,028,086 | 1,100,570 | 19.03% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $3,173,841 | 1,037,203 | 14.99% | Shares |
| Opaleye Management Inc. | $2,723,400 | 890,000 | 12.86% | Shares |
| MACKENZIE FINANCIAL CORP | $1,700,369 | 555,676 | 8.03% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1,089,360 | 356,000 | 5.15% | Put option |
| GEODE CAPITAL MANAGEMENT, LLC | $919,944 | 300,521 | 4.35% | Shares |
| BlackRock, Inc. | $687,833 | 224,782 | 3.25% | Shares |
| TWO SIGMA INVESTMENTS, LP | $654,185 | 213,786 | 3.09% | Shares |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $542,746 | 177,368 | 2.56% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $509,095 | 166,371 | 2.40% | Shares |
| HB Wealth Management, LLC | $357,026 | 116,675 | 1.69% | Shares |
| Kestra Advisory Services, LLC | $355,679 | 116,235 | 1.68% | Shares |
| STATE STREET CORP | $310,899 | 101,601 | 1.47% | Shares |
| GOLDMAN SACHS GROUP INC | $294,855 | 96,358 | 1.39% | Shares |
| Sheets Smith Investment Management | $270,259 | 73,142 | 1.28% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $264,353 | 86,390 | 1.25% | Shares |
| CITADEL ADVISORS LLC | $235,819 | 77,065 | 1.11% | Shares |
| Integrated Quantitative Investments LLC | $210,198 | 68,692 | 0.99% | Shares |
| PANAGORA ASSET MANAGEMENT INC | $202,037 | 66,025 | 0.95% | Shares |
| NORTHERN TRUST CORP | $194,714 | 63,632 | 0.92% | Shares |
| 180 WEALTH ADVISORS, LLC | $188,496 | 61,600 | 0.89% | Shares |
| CITADEL ADVISORS LLC | $178,704 | 58,400 | 0.84% | Put option |
| UBS Group AG | $160,179 | 52,346 | 0.76% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $143,826 | 47,002 | 0.68% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $140,148 | 45,800 | 0.66% | Call option |
| Integrated Wealth Concepts LLC | $138,312 | 45,200 | 0.65% | Shares |
| WOLVERINE TRADING, LLC | $129,480 | 33,200 | 0.61% | Put option |
| PRELUDE CAPITAL MANAGEMENT, LLC | $127,011 | 41,507 | 0.60% | Shares |
| WOLVERINE TRADING, LLC | $124,800 | 32,000 | 0.59% | Call option |
| PFG Investments, LLC | $111,693 | 36,501 | 0.53% | Shares |
| CHOREO, LLC | $110,925 | 36,250 | 0.52% | Shares |
| JANE STREET GROUP, LLC | $93,024 | 30,400 | 0.44% | Put option |
| TWO SIGMA ADVISERS, LP | $92,415 | 25,250 | 0.44% | Shares |
| JANE STREET GROUP, LLC | $77,767 | 25,414 | 0.37% | Shares |
| Cubist Systematic Strategies, LLC | $77,347 | 20,933 | 0.37% | Shares |
| Empowered Funds, LLC | $76,500 | 25,000 | 0.36% | Shares |
| Squarepoint Ops LLC | $47,066 | 15,381 | 0.22% | Shares |
| Corient Private Wealth LP | $45,787 | 14,963 | 0.22% | Shares |
| NewEdge Advisors, LLC | $45,677 | 14,927 | 0.22% | Shares |
| Abacus Planning Group, Inc. | $44,474 | 14,534 | 0.21% | Shares |
| SIMPLEX TRADING, LLC | $44,394 | 14,508 | 0.21% | Shares |
| Man Group plc | $40,940 | 13,379 | 0.19% | Shares |
| Vanguard Global Advisers, LLC | $38,489 | 12,578 | 0.18% | Shares |
| Weaver Consulting Group | $31,724 | 10,367 | 0.15% | Shares |
| Forum Financial Management, LP | $30,600 | 10,000 | 0.14% | Shares |
| OSAIC HOLDINGS, INC. | $27,725 | 9,061 | 0.13% | Shares |
| WELLS FARGO & COMPANY/MN | $15,300 | 5,000 | 0.07% | Shares |
| Rockefeller Capital Management L.P. | $14,725 | 4,812 | 0.07% | Shares |
| Arax Advisory Partners | $12,503 | 4,086 | 0.06% | Shares |
| SBI Securities Co., Ltd. | $11,169 | 3,650 | 0.05% | Shares |
Activists & 5%+ owners 5 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Lindsay A. Rosenwald, M.D. ×3 filings | March 20, 2026 | 0.00% | Amendment | · | SEC |
| Fortress Biotech, Inc. ×30 filings | Jan. 6, 2026 | 13.40% | Amendment | · | SEC |
| Lindsay A Rosenwald, M.D. ×2 filings | Jan. 3, 2024 | · | Initial filing | · | SEC |
| Michael S. Weiss ×4 filings | Nov. 21, 2023 | · | Initial filing | · | SEC |
| Mr. Daryl Katz, DAK Capital Inc. ×2 filings | Feb. 14, 2023 | · | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 21 insiders · 11 officers · 13 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Lindsay A. Rosenwald, M.D. | PRESIDENT, CEO & CHAIRMAN | March 18, 2026 A | 4,586,841 | 0 | 0 | $0 |
| Harlan F Weisman | Chairman and CEO | June 20, 2013 P | 30,000 | 0 | 0 | $0 |
| David Jin | Chief Financial Officer | April 1, 2026 A | 1,251,571 | 0 | 0 | $0 |
| Robyn Hunter | Chief Financial Officer | Sept. 21, 2021 S | 163,877 | 0 | 0 | $0 |
| Bobby W Sandage PHD | President | April 5, 2013 G | 22,311 | 0 | 0 | $0 |
| Noah D Beerman | Executive VP and COO | May 31, 2013 P | 15,000 | 0 | 0 | $0 |
| Michael S Weiss | Executive Vice Chairman | March 18, 2026 A | 2,276,562 | 0 | 0 | $0 |
| George Avgerinos | SVP, BIOLOGICS OPERATIONS | April 17, 2019 A | 655,170 | 0 | 0 | $0 |
| Dale Ritter | SVP & Chief Accounting Officer | May 31, 2013 P | 11,503 | 0 | 0 | $0 |
| Glenn L Cooper MD | Executive Chairman of the Board | Nov. 30, 2012 P | 43,811 | 0 | 0 | $0 |
| Karin M. Hehenberger | Executive Vice President; Chief Medical Officer | June 22, 2012 P | 20,925 | 0 | 0 | $0 |
| Dov Klein | Director | Jan. 1, 2026 A | 130,105 | 0 | 0 | $0 |
| Jimmie Harvey | Director | Jan. 1, 2026 A | 146,704 | 0 | 0 | $0 |
| Jay J Lobell | Director | Jan. 1, 2026 A | 192,397 | 0 | 0 | $0 |
| Kevin Lorenz | Director | Jan. 1, 2025 A | 73,687 | 0 | 0 | $0 |
| Lucy Lu | Director | Jan. 1, 2025 A | 61,273 | 0 | 0 | $0 |
| Eric K Rowinsky | Director | Jan. 1, 2024 A | 68,797 | 0 | 0 | $0 |
| David Jonathan Barrett | Director | Feb. 20, 2014 A | 50,000 | 0 | 0 | $0 |
| Michael W Rogers | Director | Feb. 7, 2013 A | · | 0 | 0 | $0 |
| Malcolm Hoenlein | · | Jan. 1, 2026 A | 115,747 | 0 | 0 | $0 |
| Kevin Horgan | · | April 22, 2014 M | 0 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 3 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
FBIO Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
1 analysts · 2026-09-29Mean target $5.00 +146.3%
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| FBIO | · | · | · | · | · | · |
| ALDX | $312M | -9.2 | · | · | -68.0% | · |
| SPRO | $131M | 15.5 | 39.2% | 12.8% | 18.7% | · |
| RNTX | · | -0.6 | · | · | · | · |
| GRML | · | · | · | · | -104.9% | · |
| XBIT | · | -1.6 | · | · | · | · |
| APLM | · | -2.5 | · | -128.7% | -1305.4% | · |
| IBIO | $97M | -5.5 | -75.0% | -33044.0% | -65.7% | · |
| GOSS | $724M | -4.1 | -57.7% | -351.5% | 201.8% | · |
| NMAD | · | · | · | · | · | · |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.